FY2022 Q3 Financial and R&D Update

FY2022, 2023 News Flow Daiichi-Sankyo As of Jan 2023 Key data readouts EHHERTUⓇ DESTINY-Breast06*: HR positive and HER2 low BC, chemo naïve, Ph3 Planned major publications JSMO (Mar 16-18, 2023) HER3-DXd Ph1 study: EGFR mutated NSCLC • Data update of dose escalation cohort and dose expansion cohort Dato-DXd • FY2023 H1 TROPION-Lung01*: NSCLC, 2/3L, Ph3 • FY2023 Q1 Regulatory decisions ENHERTUⓇ DESTINY-Breast04: HER2 low BC, post chemo, Ph3 JP: FY2022 Q4 . DESTINY-Lung01, 02: HER2 mutant NSCLC, 2L+, Ph2 ⚫ JP: FY2023 H1 • EU: FY2023 H2 HER3-DXd DS-5670 HERTHENA-Lung01: EGFR mutated NSCLC, 3L, registrational Ph2 • FY2022 Q4 Primary vaccination, original strain, Ph3 • FY2023 H1 Planned pivotal study initiation Quizartinib QUANTUM-First AML, 1L, Ph3 • JP/US: FY2023 H1 • EU: FY2023 H2 FLUMISTⓇ (VN-0107) Nasal seasonal influenza vaccine ⚫ JP: FY2022 Q4 DS-5670 COVID-19 mRNA subvariant vaccine, booster study, healthy volunteers, Ph3 • FY2023 H1 Bold: update from FY2022 Q2 AML: acute myeloid leukemia, BC: breast cancer, JSMO: Japanese Society of Medical Oncology, NSCLC: non-small cell lung cancer Timeline indicated is based on the current forecast and subject to change. *Event-driven study 33

View entire presentation